X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CADILA HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CADILA HEALTHCARE DR. REDDYS LAB/
CADILA HEALTHCARE
 
P/E (TTM) x 27.3 35.2 77.5% View Chart
P/BV x 2.8 9.1 31.0% View Chart
Dividend Yield % 1.0 0.7 149.2%  

Financials

 DR. REDDYS LAB   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
CADILA HEALTHCARE
Mar-16
DR. REDDYS LAB/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,383454 964.6%   
Low Rs2,750305 903.1%   
Sales per share (Unadj.) Rs920.196.1 957.5%  
Earnings per share (Unadj.) Rs126.114.9 847.9%  
Cash flow per share (Unadj.) Rs183.017.8 1,026.6%  
Dividends per share (Unadj.) Rs20.003.20 625.0%  
Dividend yield (eoy) %0.60.8 66.5%  
Book value per share (Unadj.) Rs685.852.3 1,311.9%  
Shares outstanding (eoy) m170.611,023.74 16.7%   
Bonus/Rights/Conversions ESOPFV5:1-  
Price / Sales ratio x3.93.9 98.2%   
Avg P/E ratio x28.325.5 110.9%  
P/CF ratio (eoy) x19.521.3 91.6%  
Price / Book Value ratio x5.27.3 71.6%  
Dividend payout %15.921.5 73.7%   
Avg Mkt Cap Rs m608,481388,458 156.6%   
No. of employees `00021.715.4 140.3%   
Total wages/salary Rs m31,87413,317 239.3%   
Avg. sales/employee Rs Th7,244.46,371.1 113.7%   
Avg. wages/employee Rs Th1,470.9862.4 170.6%   
Avg. net profit/employee Rs Th992.8986.1 100.7%   
INCOME DATA
Net Sales Rs m156,97898,376 159.6%  
Other income Rs m2,693941 286.2%   
Total revenues Rs m159,67199,317 160.8%   
Gross profit Rs m34,58723,829 145.1%  
Depreciation Rs m9,7053,022 321.1%   
Interest Rs m824486 169.5%   
Profit before tax Rs m26,75121,262 125.8%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m5,2375,716 91.6%   
Profit after tax Rs m21,51415,226 141.3%  
Gross profit margin %22.024.2 91.0%  
Effective tax rate %19.626.9 72.8%   
Net profit margin %13.715.5 88.5%  
BALANCE SHEET DATA
Current assets Rs m118,20144,376 266.4%   
Current liabilities Rs m68,36834,071 200.7%   
Net working cap to sales %31.710.5 303.1%  
Current ratio x1.71.3 132.7%  
Inventory Days Days6054 111.4%  
Debtors Days Days9762 155.4%  
Net fixed assets Rs m72,26547,896 150.9%   
Share capital Rs m8531,024 83.3%   
"Free" reserves Rs m111,54848,746 228.8%   
Net worth Rs m117,00953,519 218.6%   
Long term debt Rs m10,6908,964 119.3%   
Total assets Rs m200,104100,163 199.8%  
Interest coverage x33.544.7 74.8%   
Debt to equity ratio x0.10.2 54.5%  
Sales to assets ratio x0.81.0 79.9%   
Return on assets %11.215.7 71.2%  
Return on equity %18.428.4 64.6%  
Return on capital %21.634.3 63.0%  
Exports to sales %46.345.3 102.2%   
Imports to sales %9.05.9 150.8%   
Exports (fob) Rs m72,61844,537 163.1%   
Imports (cif) Rs m14,0505,838 240.7%   
Fx inflow Rs m75,40544,881 168.0%   
Fx outflow Rs m27,1159,069 299.0%   
Net fx Rs m48,29035,812 134.8%   
CASH FLOW
From Operations Rs m40,47619,938 203.0%  
From Investments Rs m-19,421-9,039 214.9%  
From Financial Activity Rs m-17,009-9,527 178.5%  
Net Cashflow Rs m4,0461,372 294.9%  

Share Holding

Indian Promoters % 25.5 74.8 34.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.3 65.1%  
FIIs % 35.3 5.9 598.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 11.0 139.1%  
Shareholders   75,885 44,069 172.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  GLENMARK PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 18, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ALEMBIC PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS